Posts

STAT+: Supreme Court strikes down use of affirmative action, a blow to efforts to diversify medical schools

STAT+: Supreme Court strikes down use of affirmative ac...

Jul 2, 2023

The U.S. Supreme Court struck down the use of affirmative action, ruling that it...

Promising Results from Gelesis Study Show Stomach-Filling Capsule as Potential Alternative to GLP-1s for Weight Loss

Promising Results from Gelesis Study Show Stomach-Filli...

Jul 1, 2023

Gelesis, a company specializing in oral hydrogel technology, received FDA cleara...

Pfizer’s Breakthrough Treatment for Severe Alopecia Areata in Adolescents Receives FDA Approval

Pfizer’s Breakthrough Treatment for Severe Alopecia Are...

Jul 1, 2023

Alopecia areata, the most prevalent form of alopecia affecting individuals of al...

Vertex and Lonza Join Forces to Open New Manufacturing Facility for the Former’s T1D Therapies

Vertex and Lonza Join Forces to Open New Manufacturing ...

Jul 1, 2023

Vertex Pharmaceuticals and Lonza have announced a strategic partnership to const...

Lilly Links Oral Obesity Drug to 15% Weight Loss, Setting the Bar for Pfizer in a Competitive Battle

Lilly Links Oral Obesity Drug to 15% Weight Loss, Setti...

Jul 1, 2023

Eli Lilly has set a benchmark in the oral obesity market by demonstrating a weig...

Eculizumab biosimilar by Turgut Ilaclari for Neuromyeli...

Jul 1, 2023

Eculizumab biosimilaris under clinical development by Turgut Ilaclari and curren...

(Glucagon + insulin human) by Abvance Therapeutics for ...

Jul 1, 2023

(Glucagon + insulin human)is under clinical development by Abvance Therapeutics ...

KP-910 by Kaken Pharmaceutical for Peripheral Neuropath...

Jul 1, 2023

KP-910is under clinical development by Kaken Pharmaceutical and currently in Pha...

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

[177Lu]Lu-rhPSMA-10.1is under clinical development by Blue Earth Therapeutics an...

ABBV-444 by AbbVie for Keratoconjunctivitis Sicca (Dry ...

Jul 1, 2023

ABBV-444is under clinical development by AbbVie and currently in Phase III for K...

XKDCT-080 by Guangdong Xiankangda Biotechnology for Col...

Jul 1, 2023

XKDCT-080is under clinical development by Guangdong Xiankangda Biotechnology and...

Immune Thrombocytopenia by NovelMed Therapeutics for Id...

Jul 1, 2023

Immune Thrombocytopeniais under clinical development by NovelMed Therapeutics an...

Cold agglutinin disease by NovelMed Therapeutics for Ac...

Jul 1, 2023

Cold agglutinin diseaseis under clinical development by NovelMed Therapeutics an...

SNK-396 by Synerk for Lipid Disorders: Likelihood of Ap...

Jul 1, 2023

SNK-396is under clinical development by Synerk and currently in Phase I for Lipi...

IN-14199 by HK inno.N for Constipation: Likelihood of A...

Jul 1, 2023

IN-14199is under clinical development by HK inno.N and currently in Phase I for ...

We have a cure for hepatitis C — so why aren’t more people getting treatment?

We have a cure for hepatitis C — so why aren’t more peo...

Jun 30, 2023

New data shows that among adults under the age of 40, only 1 in 4 people with he...